Amendments to the Specification

On page 4, replace lines 18-25 with the following:

--[4] In another preferred embodiment, the lipid blend, comprises:

(a) 1,2-dipalmitoyl-*sn*-glycero-3-phosphatidylcholine;

(b) 1,2-dipalmitoyl-*sn*-glycero-3-phosphotidic acid, ~~mono sodium~~ monosodium salt; and,

(c) *N*-(methoxypolyethylene glycol 5000 carbamoyl)-1,2-dipalmitoyl-*sn*-glycero-3-phosphatidylethanolamine, mono sodium salt.--

On page 7, replace lines 20-26 with the following:

--[30] In a preferred embodiment, in step (a), the lipids are:

(i) 1,2-dipalmitoyl-*sn*-glycero-3-phosphatidylcholine;

(ii) 1,2-dipalmitoyl-*sn*-glycero-3-phosphotidic acid, ~~mono sodium~~ monosodium salt; and,

(iii) *N*-(methoxypolyethylene glycol 5000 carbamoyl)-1,2-dipalmitoyl-*sn*-glycero-3-phosphatidylethanolamine, monosodium salt.--

On page 8, replace lines 34-38 with the following:

--[37] In another preferred embodiment, the lipid blend, comprises:

(a) 1,2-dipalmitoyl-*sn*-glycero-3-phosphatidylcholine;

(b) 1,2-dipalmitoyl-*sn*-glycero-3-phosphotidic acid, ~~mono sodium~~ monosodium salt; and,--

On page 10, replace lines 6-21 with the following:

--Lipid blend or phospholipid blend, as used herein, is intended to represent two or more lipids which have been blended. The lipid blend is generally in a powder form. Preferably, at least one of the lipids is a phospholipid. Preferably, the lipid blend contains 1,2-dipalmitoyl-*sn*-glycero-3-phosphatidylcholine (DPPC), 1,2-dipalmitoyl-*sn*-glycero-3-phosphotidic acid, ~~mono sodium~~ monosodium salt (DPPA), and *N*-(methoxypolyethylene glycol 5000 carbamoyl)-1,2-dipalmitoyl-*sn*-glycero-3-phosphatidylethanolamine, monosodium salt (MPEG5000-DPPE). The amount of each lipid present in the blend will depend on the desired end product. Preferred ratios of each lipid are described in the Examples section. A wide variety of other lipids, like those described in Unger et al, U.S. Patent No. 5,469,854, the contents of which are hereby incorporated by reference, may be used in the present process.--

On page 13, replace lines 9-20 with the following:

--Substantial dissolution is generally indicated when the mixture of lipid blend and non-aqueous solvent ~~solven~~ becomes clear. As noted previously, phospholipids are generally not water soluble. Thus, direct introduction of a blend of phospholipid blend into an aqueous environment causes the lipid blend to aggregate forming clumps that are very difficult to disperse. The present invention overcomes this limitation by dissolving the lipid blend in a non-aqueous solvent prior to introduction of the aqueous solution. This allows

one to evenly disperse the lipid blend into a liquid. The liquid dispersion can then be introduced into a desired aqueous environment.--

On page 23, replace lines 11-23 with the following:

--The preferred lipid suspension contains:

1,2-dipalmitoyl-*sn*-glycero-3-phosphotidic acid, ~~mono sodium~~ monosodium salt (DPPA);

1,2-dipalmitoyl-*sn*-glycero-3-phosphatidylcholine (DPPC);

N-(methoxypolyethylene glycol 5000 carbamoyl)-1,2-dipalmitoyol-*sn*-glycero-3-phosphatidylethanolamine, monosodium salt (MPEG5000-DPPE);

Propylene Glycol, USP;

Glycerin, USP;

Sodium Chloride, USP; and,

Water for Injection, USP.--